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Clustered regularly interspaced short palindromic repeats
(CRISPR), CRISPR-associated gene 9 (Cas9) genome editing
is set to revolutionize genetic manipulation of pathogens,
including kinetoplastids. CRISPR technology provides
the opportunity to develop scalable methods for high-
throughput production of mutant phenotypes. Here, we report
development of a CRISPR-Cas9 toolkit that allows rapid
tagging and gene knockout in diverse kinetoplastid species
without requiring the user to perform any DNA cloning. We
developed a new protocol for single-guide RNA (sgRNA)
delivery using PCR-generated DNA templates which are
transcribed in vivo by T7 RNA polymerase and an online
resource (LeishGEdit.net) for automated primer design. We
produced a set of plasmids that allows easy and scalable
generation of DNA constructs for transfections in just a few
hours. We show how these tools allow knock-in of fluorescent
protein tags, modified biotin ligase BirA*, luciferase, HaloTag
and small epitope tags, which can be fused to proteins at
the N- or C-terminus, for functional studies of proteins and
localization screening. These tools enabled generation of null
mutants in a single round of transfection in promastigote
form Leishmania major, Leishmania mexicana and bloodstream
form Trypanosoma brucei; deleted genes were undetectable in
non-clonal populations, enabling for the first time rapid and
large-scale knockout screens.
1. Introduction
Kinetoplastid parasites, including the human pathogenic
Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp., pose
a huge global burden on health and economic development;
thus the need for better diagnostic tools and medicines
for these neglected diseases remains urgent. The ability to
2017 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.
 on May 28, 2017http://rsos.royalsocietypublishing.org/Downloaded from 
2rsos.royalsocietypublishing.org
R.Soc.opensci.4:170095
................................................
generate targeted mutations in the laboratory to study mutant phenotypes has been key to the dissection
of basic parasite biology, pathogenicity mechanisms and drug resistance. These studies were facilitated
by powerful forward and reverse genetics methods [1] and whole-genome sequence information.
For T. brucei, important new insights into its basic biology [2–4] and drug-resistance mechanisms [5]
emerged from genome-scale loss-of-function screens using RNA interference (RNAi) libraries.
Trypanosoma cruzi and most Leishmania spp. lack essential components of the RNAi machinery [6]
and generation of loss-of-function mutants remains, at best, a time-consuming endeavour and largely
impossible for many multicopy gene families. Plasticity in chromosome copy numbers [7,8] further
complicates targeted mutations of many potentially important genes.
Big ‘-omics’ datasets call for quick methods to interrogate large cohorts of genes to screen, for example,
proteomics datasets for subcellular localization of proteins or to identify interaction partners within
larger complexes. In T. brucei, homologous recombination (HR) can be achieved with targeting sequences
short enough for incorporation into oligonucleotide primers for PCR-amplification of gene deletion
and tagging cassettes [9–12]. This allowed for development of powerful high-throughput gene-tagging
methods [12–14]. Leishmania require longer (more than 300 nt) homology arms for efficient and correct
integration of donor DNA [12]; targeting cassettes thus have to be assembled in a plasmid by DNA
cloning or with a two-step fusion-PCR method, both more labour intensive and less scalable than a
one-step PCR protocol.
Genome editing by clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR-
associated gene 9 (Cas9) is a transformative new technology [15,16] for precise cleavage of double-
stranded DNA by a Cas9 nuclease with sequence-specificity determined by a single-guide RNA
(sgRNA). The subsequent repair of the double-strand break provides opportunities for disruption or
precise modifications of the target locus. For apicomplexan parasites, CRISPR methods have been used
in Plasmodium spp. [17,18], Cryptosporidium [19] and enabled a genome-wide loss-of-function screen in
Toxoplasma gondii that identified new genes important in infection of human fibroblasts [20]. The first
reports of CRISPR-Cas9 gene editing in kinetoplastids, for T. cruzi [16,21,22], Leishmania donovani [23] and
Leishmania major [24], all used similar strategies for expressing Cas9 from episomal plasmids. The target-
specific sgRNAs in these studies were delivered either by transfection of in vitro transcribed sgRNA [21]
or transfection of episomal plasmids for in vivo transcription of sgRNAs from RNA Pol I [22,23] or
RNA Pol III [24] promoters. Transfection of Cas9 and sgRNA-expressing cells with a donor DNA for
homology directed repair produced precise modifications of the target locus [23], allowing for generation
of null mutants for single and multicopy genes (e.g. PFR2 in L. major [24] and T. cruzi [22]) in a single
round of transfection and tagging of T. cruzi genes at the endogenous locus [25]. Without the addition
of donor DNA, Cas9-induced double-strand breaks were repaired by a mechanism of microhomology-
mediated end joining (MMEJ), resulting in small deletions at the target site [21,23]. Hence, CRISPR
technology enables simultaneous targeting of genes in multicopy families [21,26] or on supernumerary
chromosomes, which is not possible with conventional methods.
Our aim was to exploit the efficiency of CRISPR-Cas9-mediated genome modification by integration
of donor DNA to develop a simple method for rapid and scalable production of mutant Leishmania and
other kinetoplastids. We produced Leishmania mexicana, L. major and T. brucei cell lines stably expressing
Cas9. Stably expressed T7 RNA polymerase (T7 RNAP) was used to drive sgRNA transcription in vivo
from DNA templates generated by a single PCR reaction. A set of plasmids serves as PCR templates
for rapid production of a variety of donor DNAs without the need for any DNA cloning. We show
examples of gene deletion phenotypes affecting flagellar motility, lipophosphoglycan (LPG) production
and variant surface glycoprotein (VSG) release, which were obtained in a single round of transfection
and observed in non-clonal populations as early as one week after transfection. These tools will facilitate
rapid large-scale screening of mutant phenotypes in Leishmania and other kinetoplastids.
2. Results and discussion
2.1. Constitutive expression of Cas9 in Leishmania mexicana
To enable CRISPR-Cas9 gene editing, we first engineered L. mexicana promastigote forms to express Cas9.
We transfected L. mexicana with an expression plasmid (pRM006) carrying the humanized Streptococcus
pyogenes Cas9 nuclease gene (hSpCas9 [27]) with a nuclear localization signal and three copies of
the FLAG epitope tag at the N-terminus, linked to a hygromycin resistance gene. Western blotting
confirmed expression of Cas9 in the resulting hygromycin-resistant cells (named L. mex Cas9) (electronic
supplementary material, figure S1a). We found no evidence for Cas9 toxicity: L. mex Cas9 promastigote
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Figure 1. Constitutive expression of Cas9 in L. mexicana. Growth curves of L. mexicanawild-type cells (WT) and L. mex Cas9 clone G2.
forms grew at the same rate as wild-type cells in log-phase cultures, with doubling times of 6.5 h, and
reached stationary phase at the same time and density as the wild-type (figure 1). Their morphology
appeared normal by microscopy, and asynchronously growing populations showed the same cell size
distribution as the wild-type (electronic supplementary material, figure S1b). Constitutive expression of
Cas9 thus appeared to be well tolerated by L. mexicana promastigotes.
2.2. Efficient knock-in of donor DNA with less than 30 nt homology flanks
We previously showed that integration of DNA fragments by HR in Leishmania required homology
flanks (HF; sequences at the ends of the donor DNA cassette that are identical to the target locus)
of at least 100 nt [12]. Furthermore, there was a linear relationship between success rate (number
of correct integration events per transfected cell) and HF length. HF of more than 300 nt were
required to achieve useful success rates of at least one correct transfectant per million transfected
cells [12]. Since HF of more than 100 nt cannot practically be incorporated into long oligonucleotide
primers, this precluded any attempts to generate donor DNA cassettes in a one-step PCR reaction.
Previous CRISPR-Cas9 gene editing studies in Leishmania spp. reported integration of donor DNA
with either very short HF (25 nt; [23,26]) or very long HF (1000 nt [24]) but the effect of HF length on
recombination efficiency remained unclear. To address this, we determined the relationship between
HF length and rate of correct donor DNA integration in L. mex Cas9 promastigotes. We targeted
the single copy PF16 gene (LmxM.20.1400; encoding a central pair protein of the axoneme) with a
series of donor DNA cassettes for in-frame tagging with a yellow fluorescent protein gene (YFP)
linked to a blasticidin-resistance gene with HF ranging from 24–360 nt. L. mex Cas9 was then co-
transfected with these donor DNA fragments and in vitro transcribed sgRNA, targeting a position
immediately downstream of the PF16 CDS. As a control, the same donor DNA fragments were
transfected into L. mexicana wild-type cells. Following blasticidin selection, the number of drug-
resistant cells obtained from each transfection was counted and correct integration of the tagging
cassette assessed by observation of a YFP signal in the axoneme (figure 2a). Strikingly, in L. mex
Cas9 cells the frequency of correct integration was independent of HF length; HF as short as 24 nt
resulted in correct and efficient tagging of PF16. In wild-type cells, HF shorter than 100 nt did not
produce any transfectants, consistent with previous results [12], and with 360 nt HF, L. mex Cas9 cells
yielded more than 10-fold more transfectants than wild-type cells. These results demonstrate that
CRISPR-Cas9 greatly enhances the efficiency of donor DNA integration in Leishmania. Whether this is
mediated by HR or MMEJ was not further investigated here but it is interesting to note that MMEJ
was recently reported to play a dominant role in the integration of donor DNA with short HF in
L. donovani [26].
To test whether CRISPR-Cas9 allowed for targeting of two PF16 alleles simultaneously with different
tags, we generated two DNA cassettes with 30 nt HF for tagging with YFP, linked to a blasticidin-
resistance gene, or mCherry, linked to a neomycin-resistance gene. Co-transfection of the two cassettes
with in vitro transcribed sgRNA and simultaneous selection with two drugs yielded cells with doubly
fluorescent flagella (figure 2b) at a rate of 1 × 10−6 per transfected cell. These doubly tagged cells
remained motile, indicating that expression of two tagged PF16 alleles was compatible with normal
flagellar function.
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Figure 2. Short HF allow efficient integration of donor DNA. (a) Leishmania mexicana wild-type cells (WT; grey) and L. mex Cas9 clone
G2 (red) were transfected with PF16::YFP tagging cassettes containing different length HF (24, 33, 47, 65 and 350 nt). The plot shows the
number of transfectants recovered per transfected cell. Large open circles denote blasticidin-resistant cells; small-filled circles denote
blasticidin-resistant cells with green fluorescent flagella. For wild-type cells, homology lengths of 24–65 nt yielded no drug-resistant
cells. Each data point represents the mean number of transfectants from three independent transfections. (b) Micrographs showing
PF16::YFP and PF16::mCherry (mCh) expression in L. mex Cas9 cells transfected with each tagging construct separately or combined.
Merged: phase contrast image overlaid with fluorescence channels showing YFP (green), mCh (magenta) and Hoechst-stained DNA
(cyan). Scale bar 5 µm.
2.3. In vivo transcription of PCR-amplified sgRNA templates by T7 RNAP
While in vitro transcription is a quick method for sgRNA production, we saw an opportunity to simplify
the process of sgRNA delivery further by transfecting the double-stranded DNA template used for in
vitro sgRNA transcription with T7 RNA polymerase (T7 RNAP) [28] directly into cells expressing T7
RNAP. To test this, we inserted a T7 RNAP gene [29] into L. mex Cas9 and confirmed expression of
Cas9 and T7 RNAP in the resulting L. mex Cas9 T7 cell line by Western blot (electronic supplementary
material, figure S2). These promastigotes appeared morphologically normal and their growth rate was
similar to the wild-type and L. mex Cas9 cell line (electronic supplementary material, figure S1c,d).
We tested the system by tagging three genes: PF16, small myristoylated protein 1 (SMP-1,
LmxM.20.1310) or histone H2B (LmxM.28.0210). L. mex Cas9 T7 cells were co-transfected with donor
DNA with 30 nt HF (figure 3a) and an sgRNA template for the corresponding gene (figure 3b). As
controls, cells were transfected with donor DNA alone or without any DNA. We performed these
transfections in duplicate to compare the suitability of two transfection platforms, the BTX system and
the Amaxa Nucleofector 2b, which is known to enhance transfection efficiency in kinetoplastids [30]. All
cells co-transfected with donor DNA and sgRNA template yielded drug-resistant cell lines (figure 3c)
that showed the expected fluorescence signals in the axoneme (PF16), nucleus (histone H2B) or
flagellar membrane (SMP-1) (figure 3d). The control transfections yielded no drug-resistant cells. These
results indicate that functional sgRNA was transcribed from the linear DNA fragments. In Plasmodium
falciparum, T7 RNAP has previously been used to transcribe sgRNAs in vivo from a circular plasmid
whose construction involved production of a target gene-specific sgRNA cassette followed by Gibson
assembly [31]. Our simplified protocol for delivery of sgRNA only requires transfection of a PCR product.
To test how rapidly the sgRNA templates were lost from a transfected population, DNA isolated at
different time points post transfection was analysed by PCR. This showed that sgRNA template DNA
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Figure 3. Co-transfection of twoPCR amplicons allowedprecise insertion ofmarker genes. (a) PCR-amplified donor DNA containing 30 nt
HF specific to the target locus, a fluorescent protein tag and a drug-selectable marker gene. (b) Strategy for sgRNA delivery: the sgRNA
template is produced by PCR using an oligo encoding the T7 promoter, 20 nt defining the target-site and a sequence complementary to
the 3′-end of the second oligo, comprising the sgRNA scaffold [28]. The resulting PCR product is transfected into cells for T7 RNAP-driven
transcription of the sgRNA. (c) Summary of outcome of transfections with different combinations of sgRNA templates and donor DNAs
and electroporation protocols. Green filled circles denote drug-resistant cells showing the expected fluorescent signal; red open circles
indicate failure to produce any drug-resistant transfectants. (d) Micrographs showing correct flagellar localization of PF16::YFP, nuclear
localization of H2B::YFP (thewhite colour indicates co-localization of YFP andHoechst) andflagellarmembrane localization of SMP-1::YFP
in cells that were co-transfected with the donor DNA and corresponding sgRNA template. Phase contrast imagemergedwithmCh or YFP
fluorescence channels and Hoechst-stained DNA (magenta). Scale bar 5 µm. (e) PCR-detection of the sgRNA template. Top, agarose gel
showing the results of a diagnostic PCR to test for the presence of the sgRNA template. Template DNAswere as follows. Input: 1µl of PF16
sgRNA PCR used for transfection; 5 min-48 h post transfection (p.t.): genomic DNA from cells at different time points post transfection
with PF16 sgRNA;PF16,LPG1, PF16::mCh / PF16::YFP: genomic DNA from drug-resistant cell lines reported in this study; parental:
genomic DNA from the parental cell line L. mex Cas9 T7. Bottom, diagram showing the sgRNA template and the primers used for PCR
detection.
remained present up to 8 h post transfection but was undetectable after 48 h (figure 3e), indicating loss of
the sgRNA template. Our results demonstrate that co-transfection of two PCR products is sufficient for
precise modification of a gene locus in L. mex Cas9 T7 cells, providing a rapid and scalable new method
for gene tagging in Leishmania.
2.4. pT and pPLOT plasmids enable rapid PCR-generation of donor DNA
To streamline production of donor DNA for tagging and knockouts (KO), we developed a modular
plasmid system where each plasmid serves as a template for PCR-amplification of a drug-selectable
repair cassette (figure 4 and table 1; electronic supplementary material, file S1, figure S3, tables S1,
S2 and file 5). The pPLOT plasmids for amplification of knock-in cassettes are based on the pPOT
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Figure 4. Amodular system for PCR-amplification of targeting fragments. (a) Strategy for using pT and pPLOT to generate donor DNA for
repair of Cas9-induced double-strand breaks allowing precise modification of a target locus. To delete a target gene, two sgRNAs direct
cuts to sites immediately upstream (5′) and downstream (3′) of the target gene. Repair cassettes with drug-selectable marker genes
(DrugR) and 30 nt HF specific to the target locus are PCR-amplified from pT plasmids with primers 1 and 5. The same primer pair can be
used to amplify cassettes with different drug-resistance genes. To tag a target gene, one sgRNA directs a cut immediately upstream or
downstream of the target gene, for fusing tags to the N- or C- terminus of a protein, respectively. A repair cassette with 30 nt HF specific
to the target locus, the desired tag and a drug-selectable marker gene are PCR-amplified from a pPLOT plasmid. Primer pair 1 and 2 is
used for N-terminal tagging (indicated by grey arrows), 4 and 5 for C-terminal tagging (dashed arrows). The same primer pairs can be
used to amplify a range of different tagging cassettes. Primers 3 and 6 (not shown) are used to amplify the 5′- and 3′-sgRNA templates.
(b) Diagrams showing the target gene locus before and after insertion of repair cassettes.
plasmid developed for tagging T. brucei proteins [12] and allow fusion to the 5′- or 3′-end of a target
gene in its endogenous locus, to generate fusion proteins with an N- or C-terminal tag, respectively.
Experimental validation of long gene lists from genome analysis, transcriptomics or proteomics studies
has to date been very time-consuming. Hence, one major application of pPLOT will be tagging of genes
to produce fluorescent fusion proteins for rapid screening of subcellular localization in Leishmania spp.
Other tags encompassed in the pPLOT plasmid system include small epitope tags for localization studies
or immuno-precipitation, Luciferase, the modified biotin ligase BirA* [37] for proximity-dependent
biotin labelling and the HaloTag [35] for a variety of studies including imaging, protein purification and
identification of interaction partners. pPLOT plasmids are modular to allow for easy expansion of the
repertoire by exchanging an existing tag with any sequence of interest and were also designed with all
the tags fused to three myc epitopes to simplify detection of fusion proteins on Western blots (electronic
supplementary material, figure S4).
The pT plasmids serve as templates for PCR-amplification of KO cassettes with different drug-
selectable markers (Neomycin-kanamycin phosphotransferase, Blasticidin-S deaminase and Puromycin
N-acetyltransferase). Flanking the drug-resistance genes are L. mexicana (LmxM) 5′- and 3′-untranslated
region (UTR) sequences, which were selected based on length (maximal 850 nt) and transcript abundance
(100–300 fragments per kilobase of transcript per million mapped reads, with similar expression levels
in promastigotes and amastigotes [38]) to promote robust expression of the resistance gene independent
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Table 1. pPLOT plasmids. (Available combinations of fusion tags and resistance genes are indicated by a cross. All tags are fused to amyc
epitope. Sequences are in the electronic supplementary material, file S5.)
resistance
tag refs blasticidin puromycin neomycin phleomycin
mNeonGreen [32] × ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mCherry [33] × ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10× TY [34] ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TY::HaloTag::TY [35] × ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NanoLuc luciferase [36] × ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BirA* [37] ×
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
of target locus and life cycle stage. The UTRs in each plasmid are different (see plasmid maps in the
electronic supplementary material, file S1, figure S3 and file 5) to minimize the risk of recombination
between KO constructs. The primer binding sites used to amplify the donor DNA are the same for
all pT and pPLOT plasmids and compatible with pPOTv4 plasmids [12,13] such that one primer set
can be used to amplify any KO or tagging cassette for a specific target gene. This means that a set
of just six gene-specific primers (figure 4) and one common sgRNA scaffold primer are sufficient to
produce a variety of N- and C-terminally tagged fusion proteins and a null mutant. To facilitate the use
of this versatile and economical system for high-throughput tagging and gene deletion, we designed the
required primer sequences for the whole genome of several kinetoplastid species (see methods and
the electronic supplementary material, figure S5) and developed a simple online tool for downloading
the primer sequences at http://leishgedit.net/.
2.5. One-step deletion of Leishmania mexicana PF16 produces immotile flagella
Some kinetoplastids are diploid organisms but some species and strains are aneuploid, with chromosome
copy number variations. Generation of a null mutant therefore requires excision of at least two
copies of a gene. To test whether our tools enabled generation of null mutants in a single round of
transfection, we targeted the PF16 locus again, expecting null mutants to show impaired motility. PF16 is
a conserved armadillo repeat protein of motile cilia and flagella, first discovered in mutagenesis screens
of Chlamydomonas reinhardtii [39,40]. PF16 is attached to the C1 microtubule of the central pair [40] and
required for C1 stability and motility [39]. To produce PF16 KO, L. mexicana Cas9 T7 was transfected with
two sgRNA templates to generate a double-strand break upstream and downstream of the PF16 CDS,
and with two repair cassettes generated from pT plasmids. All possible combinations pTBlast/pTNeo,
pTBlast/pTPuro and pTNeo/pTPuro were used and yielded similar results. The following analysis
refers to KO generated with the combination pTPuro/pTNeo. We employed dual drug selection to
eliminate any heterozygous cells that still harboured a copy of PF16. Microscopic examination of double
drug-resistant cell populations 6–7 days after transfection found that these cells were immotile (electronic
supplementary material, files S2 and S3). PCR analysis confirmed that the PF16 CDS was undetectable
and both drug-resistance genes were linked to the PF16 locus in these mutants (figure 5a). Sequencing of
PCR amplicons spanning the resistance cassette integration sites in the PF16 population and a PF16
clone showed that integration of the cassettes was precise, with no detectable insertions or deletions
(electronic supplementary material, figure S6) and the sgRNA template had been lost (figure 3e). These
data suggest that loss of motility was caused by deletion of PF16. Transmission electron microscopy
of the PF16 population revealed that instead of the normal 9 + 2 microtubule axoneme (figure 5b),
many axonemal profiles showed a 9 + 1 or 9 + 0 configuration (figure 5d,e), consistent with the role of
PF16 in stabilization of central pair (CP) microtubules [39]. The 9 + 2 axonemes that remained in the
PF16 population (figure 5c) were unlikely to represent a subpopulation of cells that had retained a
copy of PF16. Measurements of the angle between the paraflageller rod (PFR) and the plane bisecting
the two CP microtubules inPF16 9 + 2 axonemes showed great variation in CP orientation, with angles
ranging from −90° to +90° (mean −22.3° ± 53.5°). By contrast, in the parental cell line the CP was fixed
at a mean angle of 17.2° (±8.5°) (figure 5f,g), consistent with earlier reports of a fixed CP orientation in
kinetoplastids [41,42]. Our data indicate that the constraints on CP orientation had been lost in thePF16
mutant, similar to the phenotype observed following RNAi against PF16 in T. brucei [41,43]. To restore
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Figure 5. Knockout of PF16. (a) PCR analysis of thePF16 cell line. (i) PCR products visualized on agarose gel. P, parental cell line L. mex
Cas9 T7; KO,PF16 population; AB, cells expressing an ectopic copy of PF16. (ii) Diagram showing the PF16 locus and PCR primers (arrows)
used to test for presence of the PF16 CDS or the correct integration of the drug-resistance genes (blue boxes). (b) Transmission electron
microscopy cross section showing the 9+ 2 microtubule arrangement in flagellar axonemes of the parental cell line, scale bar 100 nm.
(c–e) Axonemes ofPF16 cells with a 9+ 2, 9+ 1 or 9+ 0 microtubule arrangement. (f ) Measurements of the angle between the
plane though the CP and the PFR; parental N= 23,PF16 N= 21. (g) Cartoon illustrating how angles shown in (f ) were measured.
PF16 expression, an ectopic copy of PF16 was introduced into PF16 cells. This restored normal motility
(electronic supplementary material, file S4), confirming that the observed phenotype was because of the
loss of PF16 and not a consequence of undefined off-target effects of CRISPR-Cas9 genome editing.
2.6. One-step deletion of Leishmania mexicana LPG1
The same KO strategy was used to delete another gene, LPG1 (LmxM.25.0010), which encodes a
galactofuranosyl transferase required for the biosynthesis of the abundant promastigote cell surface
molecule LPG. LPG plays important roles in interactions between promastigotes and the sand fly [44],
and protects Leishmania from complement lysis and modulates the immunological response to infection
(reviewed in [45]). LPG1 has previously been deleted in L. major [46] and L. mexicana promastigotes [47]
resulting in loss of LPG from the surface and accumulation of a truncated LPG (Glc-P-Man2-GlcN-PI),
lacking the phosphoglycan chain.
Following co-transfection of L. mex Cas9 T7 with two LPG1 sgRNA targeting cassettes and two repair
cassettes amplified from pTNeo and pTBlast, genomic DNA from the double drug-resistant population
and five clones was examined and confirmed loss of the LPG1 CDS (figure 6a), correct integration of the
blasticidin- (figure 6c) and neomycin- (figure 6d) resistance cassettes and loss of the sgRNA template
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Figure 6. Knockout of LPG1. (a,b) PCR analysis of theLPG1 cell line: test for the presence of the LPG1 CDS; (c) test for correct integration
of the blasticidin-resistance gene; (d) test for correct integration of the neomycin-resistance gene, lanes as in (c). Diagrams above the gel
pictures show the primers (arrows) used for PCR and size of expected product. (e) Western blot of whole-cell lysates probed with LT22.
P, parental cell line L. mex Cas9 T7; KO POP,LPG1 population; F3,LPG1 clonal cell line;+AB, cell lines expressing an ectopic copy
of LPG1.
(figure 3e). An ectopic copy of LPG1 (figure 6b) introduced into LPG1 clone F3 provided an add-
back control cell line, LPG1 [LPG1]. To test for the expression of LPG, Western blots of L. mex Cas9
T7, LPG1 and LPG [LPG1] cell lysates were probed with the monoclonal antibody LT22 which
recognizes glucosylated phosphosaccharide repeats of L. mexicana LPG [48]. In the parental cell line,
LT22 detected the expected pattern of higher molecular weight phosphoglycan compounds and LPG.
LPG was undetectable in the uncloned LPG1 population and clonal LPG1 cell lines but again present
in the addback cell line LPG [LPG1], at similar levels to the parental cell line (figure 6e). The LPG1
cells showed a stronger signal for the higher molecular weight phosphoglycan compounds than the
parental cell line. This is probably a result of the upregulation of proteophoshpoglycans in L. mexicana
LPG1 deletion mutants, first reported by Thomas Ilg [47]. These results indicate successful deletion of
LPG1 and restoration of LPG synthesis in the add-back cell line.
2.7. Rapid genome editing in Leishmania major
To facilitate adoption of CRISPR-Cas9 editing methods in different kinetoplastid species, we generated a
range of plasmids for expression of Cas9 and T7 RNAP (listed in the electronic supplementary material,
file S1 and table S3). pTB007, a single-marker plasmid for expression of hSpCas9 and T7RNAP in
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Figure 7. Targeting GPI-PLC in T. brucei bloodstream forms. (a) Localization of tagged GPI-PLC in T. brucei SmOx B4 Cas9 cells co-
transfected with sgRNA templates and donor DNA(s); one or both alleles of GPI-PLC were tagged with mNeonGreen (mNG) or TagRFP
S158 T ([51], TagRFPt), as indicated. SmOx B4 is the parental untagged cell line. Scale bar 5 µm. (b) PCR analysis of the following cell
lines: three independent GPI-PLC clones, doubly tagged cell line mNG::GPI-PLC/TagRFPt::GPI-PLC, SmOx B4 pTB011 and SmOx B4.
(i) PCR amplicons visualized on an agarose gel. (ii) diagrams showing the primers (arrows) used for PCR and size of expected product.
(c,d) Cells were subjected to hypotonic lysis for 20 min, separated into pellet (p) and supernatant (s) fractions and run together with
whole-cell lysates (w) on an SDS PAGE gel. (c)Western blot probedwith anti-GPI-PLC (arrows indicate expected bands: TagRFPt::GPI-PLC,
67.5 kDa; mNG::GPI-PLC 66.5 kDa; GPI-PLC, 40 kDa); (d) Coomassie stained gel (arrow indicates VSG; m, 50 kDa marker).
Leishmania spp. was transfected into L. major promastigotes and the resulting L. major pTB007 cells
expressed levels of Cas9 and T7RNAP similar to L. mex Cas9 T7, with no detrimental effect on cell growth
(electronic supplementary material, figure S2 and S7a,b). To test the functionality of the L. major pTB007
cell line, the PF16 (LmjF.20.1400) locus was edited, using PCR-generated sgRNA templates co-transfected
with pPLOT- or pT-derived amplicons. pPLOT tagging of PF16 with mNeonGreen (mNG) resulted in
fluorescent flagella (electronic supplementary material, figure S7c); integration of pTBlast and pTPuro
cassettes successfully replaced the PF16 CDS (electronic supplementary material, figure S7d) and motility
was severely impaired in the resulting PF16 population, as seen with the L. mex Cas9 T7 PF16 cells.
2.8. Rapid tagging and deletion of GPI-PLC in Trypanosoma brucei bloodstream forms
To enable the use of CRISPR tools in T. brucei, we introduced hSpCas9 into the T. brucei T7RNAP-
expressing cell lines SmOx B4 (bloodstream form) and SmOx P9 (procyclic form) (electronic
supplementary material, figures S2 and S8a; [49]). Cas9 expression had no effect on growth rate
(electronic supplementary material, figure S8b,c). To test whether our tools allowed rapid gene editing
in T. brucei SmOx B4 Cas9, we targeted glycosylphosphatidylinositol-specific phospholipase C (GPI-
PLC, Tb927.2.6000), a virulence factor required for the release of the GPI-anchored VSG from dying
cells [50]. In cells that had been co-transfected with a PCR-generated sgRNA template and one or
two fluorescent protein tagging cassettes with 30 nt HF amplified from the pPOTv4 template ([12],
electronic supplementary material, figure S8d), tagged GPI-PLC localized to both the flagellum and cell
body membrane with enrichment on the former (figure 7a). This was similar to the localization of YFP-
tagged GPI-PLC in an earlier report [52]. Transfections with the tagging constructs alone yielded no
drug-resistant cells, indicating that 30 nt HF were too short to generate recombinants in the absence of a
sgRNA template. Co-transfection of two sgRNA templates and two drug-resistance cassettes (amplified
from pPOT, electronic supplementary material, figure S8d) resulted in deletion of GPI-PLC in a single
step (figure 7b). Western blot analysis of the three independent GPI-PLC clones confirmed that they
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did not express any GPI-PLC protein (figure 7c). Subjected to a hypotonic lysis assay, GPI-PLC cells
were unable to release soluble VSG into the medium, consistent with the phenotype of GPI-PLC null
mutants produced by conventional sequential KO [50]. By contrast, loss of VSG from the pellet fraction
and accumulation in the supernatant was observed in the Cas9 expressing parental cell line and SmOx
B4 cells and the cell line with two tagged copies of GPI-PLC, indicating these remained functional
(figure 7d). These results show that in T. brucei bloodstream forms, like in Leishmania, Cas9 facilitates
integration of donor DNA with short HF and enables rapid modification or deletion of two alleles in
a single transfection.
3. Conclusion
Here, we report a CRISPR-Cas9 toolkit for rapid and precise gene modification by integration of donor
DNA, using engineered cell lines and drug selection of mutants. All required sgRNA and donor DNA
cassettes are generated by PCR in just a few hours without time-consuming DNA cloning. Remarkably,
one week after co-transfection of the relevant PCR products, PF16 and LPG1 were undetectable in non-
clonal drug-resistant populations. Our simple method for mutant generation allows many cell lines to be
produced in parallel; PCRs and transfections can be performed in multi-well plates, enabling rapid and
high-throughput screening of knockout phenotypes in Leishmania spp. and trypanosomes.
We have shown that these tools and protocols are applicable to different kinetoplastid species,
including T. brucei bloodstream forms. Our methods provide a platform for comparison of editing
efficiencies obtained for different sgRNA target sites or with different promoters for sgRNA
transcription, and will help to exploit other CRISPR-related technologies based on a variety of modified
forms of the Cas9 nuclease [53] to study the biology of these parasites. Our method can already be
adapted for construction of pooled screening libraries through introduction of barcodes into the repair
cassettes and should, with further development, enable genome-wide knockout screens. One priority is
to refine methods for precise marker-free editing of gene loci, for example, to introduce point mutations
without altering the genomic context and to increase the efficiency of mutations by MMEJ. We also plan to
develop an inducible system to control the timing of Cas9 cleavage, since the study of genes essential for
viability is currently not straightforward with the method described in this paper. CRISPR-Cas9 editing
promises to overcome major barriers to the study of gene function in kinetoplastids and will, for the first
time to our knowledge, enable large-scale loss-of-function screens in Leishmania spp. and T. cruzi.
4. Material and methods
4.1. Cell culture
Promastigote form L. mexicana (WHO strain MNYC/BZ/62/M379), L. major Friedlin and their genetically
modified derivatives were grown at 28°C in M199 medium (Life Technologies) supplemented with
2.2 g l−1 NaHCO3, 0.005% haemin, 40 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid pH 7.4
and 10% FCS. Relevant selection drugs (Melford Laboratories Ltd.) were added to the medium
at the following concentrations: 32 µg ml−1 Hygromycin B, 20 µg ml−1 Puromycin Dihydrochloride,
5 µg ml−1 Blasticidin S Hydrochloride, 40 µg ml−1 G-418 Disulfate, 50 µg ml−1 Nourseothricin Sulfate
and 25 µg ml−1 Phleomycin. Trypanosoma brucei SmOx B4 [49] was grown in HMI-9 [54] at 37°C in 5%
CO2, T. brucei SmOx P9 in SDM-79 [55] at 28°C. Relevant selection drugs (Melford Laboratories Ltd.)
were added to the medium at the following concentrations: 0.2 µg ml−1 Puromycin Dihydrochloride,
5 µg ml−1 Blasticidin S Hydrochloride, 5 µg ml−1 G-418 Disulfate, 5 µg/ml Hygromycin B. Cell culture
densities were measured using a CASY model TT cell counter (Roche Diagnostics) with a 60 µm capillary
and exclusion of particles with a pseudo diameter below 2.0 µm.
4.2. Transfections
Unless otherwise stated, cells were transfected in 1× Tb-BSF buffer [30] using one pulse with program
X-001 in the Amaxa Nucleofector IIb (Lonza).
For calculation of recombination rate, 107 L. mex Cas9 cells were transfected with 105 molecules of
respective DNA fragment per cell and 40 µg in vitro transcribed RNA. Cells were recovered in M199 for
8 h, then blasticidin was added and cells were plated on a 96-well plate. The mean rate of resistance from
three independent transfections was calculated from the positive wells on plates seeded with 5 × 106 cells
and 5 × 105 cells.
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For double tagging of PF16, 107 L. mex Cas9 cells were co-transfected with 3 µg of donor DNA and
30 µg in vitro transcribed sgRNA for single tags or with 5 µg of each donor DNA and 100 µg sgRNA for
double tagging.
For tests of in vivo sgRNA transcription, L. mex Cas9 T7 cells were transfected with 4 µg donor DNA
and 4 µg sgRNA template DNA. Transfections with the Amaxa Nucleofector IIb used 3 × 106 cells. For
transfections with the BTX ECM 830 square wave electroporation system, 107 cells were pulsed three
times with 1.5 kV (unipolar, 100 µs, 10s interval) in 0.4 cm gap Gene Pulser electroporation cuvettes
(BioRad).
For gene tagging with pPLOT constructs, 3 × 106 cells were transfected with the PCR reactions for
the sgRNA and donor DNA (combined volume approx. 50 µl) in a total volume of 250 µl. For gene KOs
with pT constructs, 107 cells were transfected with the PCR reactions for the two sgRNAs and two donor
DNAs (combined volume approx. 100 µl) in a total volume of 250 µl.
For T. brucei gene tagging, PCR products were ethanol precipitated, DNA pellets resuspended in
a total volume of 100 µl Tb-BSF buffer and mixed with 107 cells in 100 µl Tb-BSF buffer.
Electroporated cells were immediately transferred into pre-warmed medium and left to recover for
4–16 h before adding selection drugs. Survival of drug-resistant transfectants typically became apparent
5–7 days after transfection.
4.3. Construction of Cas9 and T7 RNAP expression plasmids
For expression of Cas9 in Leishmania, plasmid pRM006 was constructed: humanized S. pyogenes Cas9
from plasmid pX330 (Addgene #42230; [27]) was joined to Crithidia fasciculata PGKB 5′-UTR and GSPS
3′-UTR from pLENT V1 [12] and the backbone of pLENT V1, containing a phleomycin-resistance gene,
which was subsequently replaced with a hygromycin B phosphotransferase gene. Finally, fragments from
the 5′- and 3′-UTR of L. major β-tubulin from a constitutive expression plasmid [14] were inserted and the
plasmid was linearized with Pac I before transfection. Insertion of the T7 RNAP cassette with calmodulin
UTRs from pVY087 [29] into pRM006, downstream of Cas9 generated pTB007. For expression of Cas9 in
T. brucei, hSpCas9 from pX330 was inserted into pPOTv4-Puro-mNG-Puro [12] between the aldolase
and PFR2 intergenic sequences, replacing the mNG gene. The fragment containing the puromycin-
resistance gene and Cas9 expression cassette was subsequently excised and inserted into a plasmid
containing a blasticidin-resistance gene and targeting fragments for the T. brucei tubulin locus. The
resulting plasmid pTB011 was linearized with Pac I before transfection. Plasmid sequences are in the
electronic supplementary material, file S5.
4.4. Construction of pT and pPLOT plasmids
For the construction of pT plasmids, expression cassettes for the Neomycin-kanamycin phosphotrans-
ferase (NEO), Blasticidin-S deaminase (BSD) or Puromycin N-acetyltransferase (PAC) gene were made
by fusion PCR [12]; primer sequences are detailed in the electronic supplementary material, file S1. In
the first reaction, UTRs were amplified from the L. mexicana genome, in the second reaction, the UTRs
were fused to the drug-resistance genes. The resulting PCR product was joined to the Swa I fragment
of B6162 [56] containing the ampicillin-resistance gene and high-copy-number pUC origin. Plasmid
sequences are in the electronic supplementary material, file S5.
pPOTv4 [12] was used as backbone to generate pPLOT plasmids. First a triple myc epitope tag was
amplified by using two overlapping primers. This amplicon (approx. 150 bp) was used in a second
PCR as a long primer to amplify the C. fasciculata PGKB 5′-UTR or PGKA/B intergenic sequence (IG)
from pLENTv1 [12]. Products, containing the 5′-UTR or IG linked to a triple myc tag, were cloned into
pPOTv4 blast–blast mNeonGreen to make pPLOT blast–blast mNeonGreen. To generate pPLOT variants
with different resistance markers, the drug-resistance backbone, containing both blasticidin-resistance
genes, was exchanged with other drug-resistance backbones of pPOTv4 plasmids using Nhe I and Mlu I
restriction sites. To generate pPLOT variants with different tags, mNeonGreen was replaced with BirA*,
mCherry, 10×TY, TY::HaloTag::TY and NanoLuc Luciferase using Hin dIII and Bam HI sites. Plasmid
sequences are in the electronic supplementary material, file S5.
4.5. Construction of addback plasmids
The PF16 or LPG1 CDS were amplified, cloned into the Eco RI and Spe I sites of pRM005 (a version
of pRM006 with a phleomycin-resistance gene; for plasmid sequence, see the electronic supplementary
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material, file S5) and integrated into the β-tubulin locus. Primer sequences are detailed in the electronic
supplementary material, file S1. Cells transfected with addback plasmids were incubated both with
phleomycin, for selection stable transfectants, and hygromycin, for maintenance of the pRM006 Cas9
cassette, which contained the same targeting sites as pRM005.
4.6. PCR-amplification of targeting fragments
For recombination rate measurements, PCR-amplification of donor DNA for PF16 tagging used the
same primers as [12]. The DNA template was pLENT-PF16-YFPTY_Var4.4, derived from pLENT-
PF16::eGFP [12] by replacing the eGFP-PGKA-PGKB UTR cassette with eYFP and the IG downstream
of LmxM.34.1670 (60S ribosomal protein L26). For tests of in vivo sgRNA transcription, eYFP cassettes
with HF targeting SMP-1, histone 2B or PF16 were PCR-amplified from pLENT-PF16-YFPTY_Var4.4. For
double tagging of PF16, the mCherry and eYFP cassettes were PCR-amplified from pLENTv1 and v2 [12],
respectively.
For amplification of pPLOT and pT cassettes, 30 ng circular pPLOT or pT plasmid, 0.2 mM dNTPs,
2 µM each of gene-specific forward and reverse primers and 1 unit HiFi Polymerase (Roche) were
mixed in 1× HiFi reaction buffer with MgCl2 (Roche), supplemented with 1.875 mM MgCl2 (final MgCl2
concentration, 3.375 mM) and 3% (v/v) DMSO, 40 µl total volume. PCR steps were 5 min at 94°C followed
by 40 cycles of 30 s at 94°C, 30 s at 65°C, 2 min 15 s at 72°C followed by a final elongation step for 7 min
at 72°C. Two microlitres of this reaction was run on a 1% agarose gel to check for the presence of the
expected product. The remainder was heat-sterilized at 94°C for 5 min and used for transfection without
further purification.
For targeting of GPI-PLC in T. brucei SmOx B4, targeting cassettes were amplified from pPOTv4
plasmids [12] using the same PCR conditions as above.
4.7. PCR-amplification of sgRNA templates
For amplification of sgRNA templates, 0.2 mM dNTPs, 2 µM each of primer G00 (sgRNA scaffold) and a
gene-specific forward primer and 1 unit HiFi Polymerase (Roche) were mixed in 1× HiFi reaction buffer
with MgCl2 (Roche), 20 µl total volume. PCR steps were 30 s at 98°C followed by 35 cycles of 10 s at 98°C,
30 s at 60°C, 15 s at 72°C. Two microlitres of this reaction was run on a 2% agarose gel to check for the
presence of the expected product. The remainder was heat-sterilized at 94°C for 5 min and transfected
without further purification. Primer sequences are detailed in the electronic supplementary material,
file S1.
4.8. Diagnostic PCRs
To screen for loss of the target gene in KO cell lines, genomic DNA was isolated 10–14 days post
transfection with the DNeasy Blood & Tissue Kit (Qiagen). One hundred nanograms of isolated DNA
was mixed with 0.2 mM dNTPs, 2 µM forward primer and reverse primer, 1 unit HiFi Polymerase (Roche)
and 1× HiFi reaction buffer supplemented with MgCl2 (Roche), 20 µl total volume. PCR steps were 5 min
at 94°C followed by 35 cycles of 30 s at 94°C, 5 s at 60°C, 50 s at 72°C followed by a final elongation step
for 7 min at 72°C. Five microlitres of this reaction was run on a 2% agarose gel to check for the presence of
the expected product. To test for the presence of the sgRNA template in cells, genomic DNA was isolated
from established cell lines or from freshly transfected cultures and analysed by PCR as described above,
except that PCR steps were 5 min at 94°C followed by 30 cycles of 20 s at 94°C, 10 s at 65°C, 15 s at 72°C
followed by a final elongation step for 7 min at 72°C. Primer sequences are detailed in the electronic
supplementary material, file S1.
4.9. Sanger sequencing
To sequence construct integration sites, PCR amplicons were run on a 2% agarose gel, the band
excised from the gel and purified using the QIAquick Gel Extraction Kit (Qiagen). Sanger sequencing
of the amplicon was performed by Source BioScience. Primer sequences are detailed in the electronic
supplementary material, file S1.
4.10. Automated design of sgRNA and primers
For the design of sgRNA primers, a 45 bp window upstream of the start codon and downstream of the
stop codon was searched for a guide RNA sequence. The Eukaryotic Pathogen CRISPR guide RNA/DNA
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Design Tool (http://grna.ctegd.uga.edu) was used to identify guide RNA sequences, using the default
parameters (SpCas9: gRNA length 20; PAM: NGG; off-target PAM: NAG, NGA) and the highest scoring
20 nt guide RNA sequence was selected. If no guide RNA site was found, the window was extended
to 75 bp and then to a maximal distance of 105 bp. Primers for amplification of the targeting cassettes
used in this study were designed to contain 30 nt of sequence immediately adjacent to the guide RNA
search window. To reduce the distance between the Cas9 cut site and the HF, the primer design was
subsequently optimized by placing the 30 nt HF sequence immediately adjacent to the guide RNA target
sequence. This approach identified primers for 9097 of 9169 annotated genes in L. mexicana (using RNA-
seq based gene models defined in [38], excluding only 72 genes owing to gaps in the current genome
assembly), 8390 of 8400 L. major Friedlin genes, 7861 of 8195 L. donovani BPK282A1 genes, 11153 of 11567
T. brucei TREU 927 genes and 9230 of 11348 T. cruzi Dmc28 genes. Primer sequences can be downloaded
from http://leishgedit.net/. To assess the specificity of each guide RNA, the identified sequences (23 nt,
including the protospacer adjacent motif NGG) were aligned against the respective genome and the
number of matches was recorded for each guide RNA (electronic supplementary material, figure S5),
confirming that the vast majority of selected sites are unique in the genome.
4.11. In vitro transcription of sgRNA
sgRNA was generated by in vitro transcription of PCR-generated sgRNA templates [28] using the
MEGAshortscript T7 Transcription Kit (Thermo Fisher Scientific) following the manufacturer’s protocol.
4.12. Western blots
Cell lysates were prepared by washing cells once in phosphate buffered saline (PBS) then heating in 1×
Laemmli buffer for either 10 min at 60°C (for detection of FLAG, T7 RNAP and myc), 3 min at 100°C
(detection of LPG) or 5 min at 100°C (detection of GPI-PLC). Approximately 4 × 106 cell equivalents
for Leishmania promastigotes and 1 × 106 cell equivalents for Trypanosoma parasites were loaded
and subjected to electrophoresis on 10% SDS-polyacrylamide gels and transferred to nitrocellulose
membranes (GE Healthcare). The membranes were incubated in blocking buffer for 1 h then probed
for 1 h with primary antibody, washed in Tris buffered saline with 0.05% (w/v) Tween 20 (TBST),
incubated for 1 h with secondary horseradish peroxidase-conjugated antibody, washed in TBST and
visualized by addition of the ECL chemiluminescent detection system (PerkinElmer) and exposure to
autoradiography film (Carestream). Details of antibodies, dilutions and buffers can be found in the
electronic supplementary material, file S1.
4.13. Hypotonic cell lysis
Hypotonic cell lysis was performed similarly to [52]. 1 × 107 cells were harvested from a culture at 1 × 106
cells ml–1. Cells were washed in 1 ml PBS supplemented with 10 mM glucose and 46 mM sucrose, pH 7.6
(vPBS) and centrifuged again at 800 g for 10 min. The cells were resuspended in 100 µl of 0.1 mM Tosyl-
L-lysyl-chloromethane hydrochloride (TLCK; Sigma) diluted in water and incubated for 20 min at room
temperature. Samples were centrifuged at 14 000g for 4 min. Subsequently, supernatant and pellet were
separated and 5× Laemmli buffer was added to a final concentration of 1× respectively. Samples were
boiled and 1 × 106 cell equivalents analysed by SDS PAGE and Western blotting as above. Gels were
stained for 30 min with Coomassie brilliant blue (Sigma).
4.14. Fluorescence microscopy
Leishmania cells expressing fluorescent fusion proteins were imaged live. Samples were prepared as
described in [57]. For T. brucei bloodstream forms, cells from 1 ml of culture (1 × 106 cells ml−1) were
centrifuged at 800g for 3 min, washed in 1 ml vPBS, centrifuged again and resuspended in 30 µl vPBS
containing 4% (v/v) formaldehyde. Cells were immediately imaged with a 63× NA 1.4 objective lens
on a DM5500 B microscope (Leica Microsystems) with a Neo sCMOS camera (Andor Technology) at the
ambient temperature of 25–28°C.
4.15. Transmission electron microscopy
Cells in mid-log phase were fixed in 2.5% glutaraldehyde by addition of 1/10 volume of 25%
glutaraldehyde directly to the culture and incubated at room temperature for 5 min. Fixed cells were
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post-fixed in osmium tetroxide, stained with uranyl acetate and embedded in Agar 100 epoxy resin
as described in [58]. Sections (90 nm) were cut on an Ultracut 7 microtome (Leica), post stained with
lead citrate and imaged in a Tecnai 12 transmission electron microscope (Hillsboro, OR, USA) at 120 kV.
Images were captured with a Gatan OneView 4 k × 4 k CMOS camera using GATAN MICROSCOPY SUITE
3 software (Gatan, USA) and processed in IMAGEJ.
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